Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Rnaseq

Research Leaders

5 sponsors active, led by George Washington University

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03383211Completed

Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers

Showing all 1 trials

Research Network

Common Treatments

  • Rnaseq1

Active Sponsors

  • George Washington University1
  • Children's National Research Institute1
  • Universitatea de Stat de Medicina si Farmacie Nicolae Testemiţanu1
  • SeqLL, Inc.1
  • DC-Center for Aids Research (DC-CFAR)1

Top Investigators

Related Conditions

  • Hiv Infections1
  • Immune Tolerance1
  • Neonatal Infection1

Activity Timeline